ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,637.36
0.23%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arcturus Therapeutics Holdings Inc (ARCT)

  7. Arcturus Therapeutics Holdings Inc (ARCT) News

ARCT

Arcturus Therapeutics (ARCT)

Arcturus Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARCT
DateTimeSourceHeadlineSymbolCompany
05/28/20245:30AMBusiness WireArcturus Therapeutics Announces Positive Development for Cystic Fibrosis ProgramNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/22/20246:00AMGlobeNewswire Inc.Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer VaccinesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/20/20247:30AMBusiness WireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/20/20247:30AMPR Newswire (US)Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 VaccineNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/15/20243:01PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
05/08/20243:01PMBusiness WireArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
04/25/20243:01PMBusiness WireArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/07/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
03/07/20243:01PMBusiness WireArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/26/20248:00AMBusiness WireArcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/23/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/22/20247:30AMBusiness WireArcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/20/20248:00AMBusiness WireArcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024NASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/05/20247:30AMBusiness WireNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
02/05/20247:30AMPR Newswire (US)New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/21/20237:00AMBusiness WireCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/21/20237:00AMPR Newswire (US)CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine BoosterNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/19/20237:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
12/04/20237:30AMBusiness WireArcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/28/20237:05AMPR Newswire (US)Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/28/20237:00AMBusiness WireJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in AdultsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/27/20238:13AMDow Jones NewsArcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/27/20237:30AMBusiness WireArcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic FibrosisNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/15/20237:51AMIH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/14/20233:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARCTArcturus Therapeutics Holdings Inc
11/14/20233:01PMBusiness WireArcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline ProgressNASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/25/20233:01PMBusiness WireArcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023NASDAQ:ARCTArcturus Therapeutics Holdings Inc
10/23/20233:01PMBusiness WireArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesNASDAQ:ARCTArcturus Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ARCT

Your Recent History

LSE
46WZ
Bank Mont. 60
BIT
P21MT4
NLBNPIT21MT4 20240918 5800
USOTC
DRTFF
Desert Control AS (GM)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved